IPic Entertainment Inc through its subsidiaries owns and operates the restaurant, full-service bar, theater auditoriums with in-theater dining venues for private events, family and business functions and other corporate-sponsored events. The company operates screens at different locations including Texas, New York, New Jersey, Illinois, California, Florida, Wisconsin, Arizona, Washington, and Maryland. Its maximum revenue is generated from food and beverages. Its restaurant brands include City Perch Kitchen + Bar, Tanzy, The Tuck Room, The Tuck Room Tavern and iPic Express.

IPic Entertainment

IPIC ENTERTAINMENT INC A by iPic Entertainment Inc.

<h3>GAINERS:</h3>
<ul>
<li><a href="https://quotes.benzinga.com/quote/TLRY" target="_blank">Tilray</a>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tlry#NASDAQ">TLRY</a>) shares closed up 25.77% at $16.01</li>
<li><a href="https://quotes.benzinga.com/quote/MMNFF" target="_blank">MedMen Enterprises</a>&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/mmnff#OTC">MMNFF</a>) shares closed up 14.93% at $0.24</li>
<li><a href="https://quotes.benzinga.com/quote/OGI" target="_blank">OrganiGram Holdings</a>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ogi#NASDAQ">OGI</a>) shares closed up 10.98% at $2.73</li>
<li><a href="https://quotes.benzinga.com/quote/SOL" target="_blank">ReneSola</a>&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sol#NYSE">SOL</a>) shares closed up 8.78% at $7.43</li>
<li><a href="https://quotes.benzinga.com/quote/SNDL" target="_blank">Sundial Growers</a>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sndl#NASDAQ">SNDL</a>) shares closed up 8.14% at $0.85</li>
<li><a href="https://quotes.benzinga.com/quote/CRON" target="_blank">Cronos Group</a>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cron#NASDAQ">CRON</a>) shares closed up 7.15% at $7.64</li>
<li><a href="https://quotes.benzinga.com/quote/HEXO" target="_blank">HEXO</a>&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hexo#NYSE">HEXO</a>) shares closed up 7% at $4.28</li>
<li><a href="https://quotes.benzinga.com/quote/CGC" target="_blank">Canopy Growth</a>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NASDAQ">CGC</a>) shares closed up 6.7% at $19.60</li>
<li><a href="https://quotes.benzinga.com/quote/ACB" target="_blank">Aurora Cannabis</a>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acb#NASDAQ">ACB</a>) shares closed up 6.58% at $7.29</li>
<li><a href="https://quotes.benzinga.com/quote/CRBP" target="_blank">Corbus Pharmaceuticals</a>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crbp#NASDAQ">CRBP</a>) shares closed up 6.47% at $1.48</li>
<li><a href="https://quotes.benzinga.com/quote/VFF" target="_blank">Village Farms Intl</a>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vff#NASDAQ">VFF</a>) shares closed up 6.34% at $9.89</li>
<li><a href="https://quotes.benzinga.com/quote/GRWG" target="_blank">GrowGeneration</a>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grwg#NASDAQ">GRWG</a>) shares closed up 5.59% at $41.92</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://quotes.benzinga.com/quote/IVITF" target="_blank">Invictus MD Strategies</a>&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/ivitf#OTC">IVITF</a>) shares closed down 8.73% at $0.03</li>
<li><a href="https://quotes.benzinga.com/quote/CURR" target="_blank">CURE Pharmaceutical Hldg</a>&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/curr#OTC">CURR</a>) shares closed down 8.2% at $0.56</li>
<li><a href="https://quotes.benzinga.com/quote/HSTRF" target="_blank">Hollister Biosciences</a>&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/hstrf#OTC">HSTRF</a>) shares closed down 6.59% at $0.2</li>
<li><a href="https://quotes.benzinga.com/quote/GENE" target="_blank">Genetic Technologies</a>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gene#NASDAQ">GENE</a>) shares closed down 5% at $3.42</li>
<li><a href="https://quotes.benzinga.com/quote/MBII" target="_blank">Marrone Bio Innovations</a>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mbii#NASDAQ">MBII</a>) shares closed down 3.62% at $1.33</li>
<li><a href="https://quotes.benzinga.com/quote/MGCLF" target="_blank">MGC Pharmaceuticals</a>&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/mgclf#OTC">MGCLF</a>) shares closed down 3.17% at $0.03</li>
</ul>
<a href="https://www.benzinga.com/cannabis/stocks/">Check out a full list of cannabis stock movers in real-time following this link.</a>
Lead image by Ilona Szentivanyi. Copyright: Benzinga.

Cannabis

Penny Stocks

Small Cap

After-Hours Center

Markets

Movers

Trading Ideas

CRBP

CRON

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

GENE

GRWG

HEXO

HSTRF

IVITF

MBII

MGCLF

MMNFF

SNDL

TLRY

Bullish Sentiment Pushing Cannabis Stocks Up, Check Out Top Movers For July 28, 2021

More investors have been turning to alternative investments for higher potential returns and to diversify their portfolios with assets that have little correlation with the stock market.
The increased activity in alternative investments has spurred demand for platforms that lower the barriers to entry for alternative asset classes and simplify the process for investors.&nbsp;
Art As An Investment: One type of alternative investment that has been attracting increased interest is contemporary artwork. This isn&rsquo;t surprising considering that this asset class has provided a 14% annual return over the last 25 years, according to <a href="https://www.benzinga.com/go/masterworks-research">research conducted by Masterworks</a>, and 23% returns during years of high inflation.
Investing in this type of artwork has historically been reserved for a select class of investors, since the highest demand pieces sell for millions of dollars.
<a href="https://www.benzinga.com/go/masterworks">Masterworks</a> has created a platform where investors can buy shares of carefully selected pieces of iconic artwork as easily as buying stocks.
The average investor can now participate in this exclusive asset class by purchasing shares in Masterworks&rsquo; offerings as well as buy and sell shares on the secondary market. There is no account minimum on the platform, but the investment required for each piece of artwork varies based on the offering.
Shares on the platform&rsquo;s secondary market are currently priced as low as $20 for some pieces.&nbsp;
How To Invest: The process for signing up for Masterworks and gaining access to investments is simple, especially since you don&rsquo;t have to be an accredited investor. Once your membership is set up and you connect your bank account you&rsquo;ll be able to start buying and selling shares of some of the most famous pieces of contemporary art on the planet.
Visit the <a href="https://www.benzinga.com/go/masterworks">Masterworks platform here</a> to find out more.
Photo: Steve Johnson on Unsplash.

Crowdsourcing

General

How Investors Can Trade Shares Of Appreciating Artwork Like Stocks

Netflix Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nflx#NASDAQ">NFLX</a>) has become the first major Hollywood studio to mandate COVID-19 vaccinations for the actors in its U.S.-based productions and the crew members who come into contact with them while on a set.
What Happened: According to a <a href="https://deadline.com/2021/07/netflix-to-require-covid-vaccinations-for-all-actors-on-us-productions-1234801577/">Deadline</a> report, the major studios and the film industry unions agreed upon return-to-work protocols that enabled producers &ldquo;to implement mandatory vaccination policies for casts and crew in Zone A on a production-by-production basis.&rdquo; The term &ldquo;Zone A&rdquo; applies to a film&rsquo;s cast and the crew that interacts with them.
While individual productions, such as the Starz/UCP series &quot;Gaslit,&rdquo; adopted mandatory vaccination requirements &mdash;&nbsp;the series&rsquo; star&nbsp;Sean Penn&nbsp;refused to work unless that mandate was enacted &mdash;&nbsp;Netflix is the first studio to implement this policy across the board, with potential exceptions for people who declined the vaccine for age, medical and religious reasons.
Related Link: <a href="https://www.benzinga.com/news/21/07/22150705/anthony-hopkins-film-zero-contact-to-premiere-as-nft">Anthony Hopkins Film &#39;Zero Contact&#39; To Premiere As NFT</a>
Why It Happened: Netflix&rsquo;s policy comes as a fourth wave of COVID-19 has increased infection rates and hospitalizations across the country. To combat this new wave, Los Angeles County reinstated its mask mandate for all residents, including those who are fully vaccinated.
Last week, Los Angeles County recorded a 4% increase positive test rates, with 20% those cases coming from vaccinated patients.
Photo: Vinzenz Lorenz M from Pixabay.
&nbsp;

News

Media

NFLX

Netflix Mandates COVID-19 Vaccinations For Actors And Surrounding Crews On US Productions

Forterra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRTA#NASDAQ">FRTA</a>) reported quarterly earnings of $0.52 per share. This is a 30 percent increase over earnings of $0.40 per share from the same period last year. The company reported $492.80 million in sales this quarter. This is a 15.63 percent increase over sales of $426.19 million the same period last year.

Earnings

FRTA

Forterra Q2 EPS $0.52 Up From $0.40 YoY, Sales $492.80M Up From $426.19M YoY

Enviva Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVA#NYSE">EVA</a>) reported quarterly sales of $285.00 million which beat the analyst consensus estimate of $238.80 million by 19.35 percent. This is a 69.93 percent increase over sales of $167.71 million the same period last year.

Enviva Partners Q2 Sales $285.00M Beat $238.80M Estimate

Atai Life Sciences (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atai#NASDAQ">ATAI</a>) is launching a new company that will interact with its portfolio of psychedelics and tech start-ups looking at novel mental health treatments.
InnarisBio Inc., as the company has been baptized, is being launched as a collaboration between Atai and UniQuest, a company managing and commercializing intellectual property developed by The University of Queensland in Australia.
InnarisBio&rsquo;s mission is to perfect intranasal drug delivery technology to improve treatments for mental health disorders. Its &ldquo;sol-gel intranasal drug delivery platform technology&rdquo; was developed in the laboratory of researcher Dr. Harendra Parekh at the University of Queensland.
The &ldquo;nose-to-brain&rdquo; technology delivers pharmaceutical compounds as a liquid at room temperature which becomes a gel at body temperature.
&ldquo;InnarisBio aims to be a revolutionary technology company for intranasal drug delivery in the treatment of CNS [central nervous system] disorders,&rdquo; said Florian Brand, CEO and co-founder of Atai.&nbsp;
According to the company, traditional drug delivery methods can be problematic in the treatment of central nervous system disorders due to the blood-brain barrier that restricts the entry of therapeutic agents in&nbsp;the central nervous system. Nose-to-brain delivery has the potential to be a painless and non-invasive administration route.
Brand said the newly-formed company has the potential to be superior to other intranasal drug delivery methods available by improving uptake through mucoadhesion in the nose, thus reducing dose administered and dosing frequency.&nbsp;
Atai plans to explore the potential use of this technology for a variety of psychedelic and non-psychedelic compounds under its development.
Photo by&nbsp;British Columbia Institute of Technology (BCIT) on Wikimedia Commons.

ATAI

Atai Launches New "Nose-To-Brain" Drug Delivery Company To Interact With Its Portfolio Of Psychedelics Subsidiaries

<a href="https://twitter.com/BNODesk/status/1420497035296391170" title="https://twitter.com/BNODesk/status/1420497035296391170">https://twitter.com/BNODesk/status/1420497035296391170</a>

Health Care

Global

iShares MSCI Israel Capped Investable Market Index Fund

'Israel's Health Ministry says team of experts recommends 3rd dose of COVID-19 vaccine for older population' -BNO

Customers Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUBI#NYSE">CUBI</a>) reported quarterly earnings of $1.72 per share which missed the analyst consensus estimate of $2.05 by 16.1 percent. This is a 181.97 percent increase over earnings of $0.61 per share from the same period last year.

CUBI

Customers Bancorp Q2 EPS $1.72 Misses $2.05 Estimate

Class A Common Stock of the Combined Company Expected to Begin Trading on Nasdaq Under the Symbol &ldquo;CYXT&rdquo; on July 30, 2021
NEW YORK--(BUSINESS WIRE)-- Starboard Value Acquisition Corp. (&ldquo;SVAC&rdquo;) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVAC#NASDAQ">SVAC</a>), a U.S. publicly-traded special purpose acquisition company, today announced that its stockholders voted to approve the previously announced business combination (the &ldquo;Business Combination&rdquo;) with Cyxtera Technologies, Inc. (&ldquo;Cyxtera&rdquo;), a global data center leader in retail colocation and interconnection services.
Stockholders voted to approve the Business Combination during a Special Meeting held earlier today, and a Form 8-K disclosing the final voting results is expected to soon be filed with the Securities and Exchange Commission. Upon consummation of the Business Combination, 106,100,000 shares of Class A common stock will be issued to SIS Holdings LP, 10,105,863 shares of Class A common stock will be issued to SVAC&rsquo;s initial stockholders, an aggregate of 25,000,000 shares of Class A common stock will be issued to the PIPE investors and 10,526,315 shares of Class A common stock will be issued to the forward purchasers. Holders of 26,176,891 shares of SVAC Class A common stock have elected to redeem in connection with the Business Combination. As a result of the Business Combination, the post-Business Combination company will have 165,978,740 shares of Class A common stock outstanding and $493,000,000 in total cash from the transaction available before fees, expenses and debt amortization.
The closing of the Business Combination is anticipated to take place on July 29, 2021, subject to the satisfaction or waiver of customary closing conditions under the merger agreement entered into in connection with the Business Combination. In accordance with SVAC&rsquo;s amended and restated certificate of incorporation, SVAC will effect a distribution of 6,737,242 warrants (the &ldquo;Warrant Distribution&rdquo;) immediately prior to the consummation of the Business Combination as described in the Proxy Statement. Public stockholders who exercised their redemption rights in connection with the Business Combination are not entitled to receive any Warrant Distribution in respect of such redeemed public shares. SVAC has set 5:00 p.m. Eastern Time on the date immediately prior to the consummation of the Business Combination as the record date (the &ldquo;Record Date&rdquo;) for the Warrant Distribution and only holders of public shares on the Record Date will be entitled to participate in the Warrant Distribution. Assuming the Business Combination is consummated on July 29, 2021, the Record Date for the Warrant Distribution will be 5:00 p.m. Eastern Time on July 28, 2021, and eligible public stockholders will receive approximately .34 warrants per share of common stock as a result of the Warrant Distribution.
Following the consummation of the Business Combination, the combined company will be renamed Cyxtera Technologies, Inc. and its Class A common stock and warrants are expected to begin trading on the Nasdaq Global Select Market beginning on July 30, 2021 under the ticker symbols &ldquo;CYXT&rdquo; and &ldquo;CYXTW&rdquo; respectively.

SVAC

Starboard Value Acquisition Corp. Announces Stockholder Approval of Business Combination with Cyxtera Technologies, Inc.;

Dividends

Cactus Raises Dividend From $0.09 To $0.10/Share

Cactus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHD#NYSE">WHD</a>) reported quarterly earnings of $0.16 per share which missed the analyst consensus estimate of $0.18 by 11.11 percent. This is a 60 percent increase over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $108.90 million which beat the analyst consensus estimate of $101.60 million by 7.19 percent. This is a 63.64 percent increase over sales of $66.55 million the same period last year.

Cactus Q2 Adj. EPS $0.16 Misses $0.18 Estimate, Sales $108.90M Beat $101.60M Estimate

CRUS

Cirrus Logic Entered Into A Capacity Reservation, Wafer Supply Commitment Agreement With GlobalFoundries Singapore

Offerings

VKTX

Viking Therapeutics S-3 Shows Registration For $600M Mixed Securities Shelf Offering

TSX:CJ

Cardinal Energy Q2 Adj. Funds Flow $0.16/Share

IPOs

Metals Acquisition Corp. Prices 25M Share IPO At $10/Share

Guidance

PYPL

PayPal Earlier Reported Sees Q3 Net Revenue ~$6.15B-~$6.25B Vs. $6.43B Est., Sees Q3 Non-GAAP EPS ~$1.07 Vs. $1.14 Est.

Shares of PPD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPD#NASDAQ">PPD</a>) were flat&nbsp;in after-market trading after the company reported Q2 results.
<h2>Quarterly Results</h2>
Earnings per share were up 56.00% year over year to $0.39, which beat the estimate of $0.33.
Revenue of $1,575,000,000 rose by 55.79% year over year, which beat the estimate of $1,320,000,000.
<h2>Guidance</h2>
Earnings guidance hasn&#39;t been issued by the company for now.
Revenue guidance hasn&#39;t been issued by the company for now.
<h2>Price Action</h2>
Company&#39;s 52-week high was at $46.63
Company&#39;s 52-week low was at $28.00
Price action over last quarter: down 0.30%
<h2>Company Description</h2>
PPD is a global contract research organization that provides clinical trial and laboratory services to pharmaceutical, device, and diagnostic firms. The clinical development services segment offers outsourced trial services, spanning early- and late-stage trials, as well as peri- and post-approval trials, and the laboratory services segment includes both advanced lab testing and central lab services. The company was taken private in 2011 and went public again in 2020.. Thermo Fisher Scientific announced it will acquire PPD for $17.4 billion, which is scheduled to close by the end of 2021.

Recap: PPD Q2 Earnings

PPD Says Is Not Providing Financial Guidance Due To Proposed Merger With Thermo Fisher

Ford CFO Says Lost About 700K Units Of Vehicle Production In Q2 Due To Chip Shortage, As Co. Had Previously Forecast

Updated Full Year 2021 Guidance2
GFL also provided its updated guidance for 2021 assuming a CAD/US exchange rate of 1.25 for the remainder of the year compared to 1.27 in our original guidance:
<ul>
<li>Revenue is estimated to be between $5,225 million and $5,275 million</li>
<li>Adjusted EBITDA is estimated to be between $1,400 million and $1,415 million</li>
<li>Adjusted Free Cash Flow is estimated to be between $510 million and $520 million</li>
</ul>

Recent Quotes

Analyst Ratings

Related Companies

IPic Entertainment Frequently Asked Questions

How do I buy IPic Entertainment (IPIC) stock?

Who are IPic Entertainment's (IPIC) competitors?

What is the target price for IPic Entertainment (IPIC) stock?

Current Stock Price for IPic Entertainment (IPIC)?

Does IPic Entertainment (IPIC) pay a dividend?

When is IPic Entertainment (OTC:IPIC) reporting earnings?

Is IPic Entertainment (IPIC) going to split?

What sector and industry does IPic Entertainment (IPIC) operate in?